EP4008348A4 - BISPECIFIC ANTIBODY - Google Patents
BISPECIFIC ANTIBODY Download PDFInfo
- Publication number
- EP4008348A4 EP4008348A4 EP20846826.4A EP20846826A EP4008348A4 EP 4008348 A4 EP4008348 A4 EP 4008348A4 EP 20846826 A EP20846826 A EP 20846826A EP 4008348 A4 EP4008348 A4 EP 4008348A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bispecific antibody
- bispecific
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019139751 | 2019-07-30 | ||
PCT/JP2020/028972 WO2021020416A1 (ja) | 2019-07-30 | 2020-07-29 | 二重特異性抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4008348A1 EP4008348A1 (en) | 2022-06-08 |
EP4008348A4 true EP4008348A4 (en) | 2023-11-15 |
Family
ID=74229916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20846826.4A Pending EP4008348A4 (en) | 2019-07-30 | 2020-07-29 | BISPECIFIC ANTIBODY |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220281977A1 (ja) |
EP (1) | EP4008348A4 (ja) |
JP (2) | JP6856183B1 (ja) |
KR (1) | KR20220039720A (ja) |
CN (1) | CN114174343A (ja) |
AU (1) | AU2020322765A1 (ja) |
BR (1) | BR112022001473A2 (ja) |
CA (1) | CA3149309A1 (ja) |
IL (1) | IL290050A (ja) |
MX (1) | MX2022000971A (ja) |
TW (1) | TW202118790A (ja) |
WO (1) | WO2021020416A1 (ja) |
ZA (1) | ZA202201247B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101027427B1 (ko) * | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
US20110280878A1 (en) * | 2003-01-23 | 2011-11-17 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
US20120003210A1 (en) * | 2003-11-12 | 2012-01-05 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP2147594B1 (en) * | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
US20180186875A1 (en) * | 2015-09-25 | 2018-07-05 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
US20180355061A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that Specifically Bind PD-1 and Methods of Use |
US20190211100A1 (en) * | 2015-07-10 | 2019-07-11 | Merus N.V. | Human CD3 Binding Antibody |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
IL102490A0 (en) | 1991-07-15 | 1993-01-14 | Wellcome Found | Production of antibodies |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
DK2163640T3 (da) | 1999-04-15 | 2012-03-05 | Crucell Holland Bv | Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
NZ519012A (en) | 2001-05-21 | 2003-10-31 | Orgapack Gmbh | Manually actuated strapping unit for wrapping a steel strap around a packaged item |
US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
JP2004072286A (ja) | 2002-08-05 | 2004-03-04 | Nippon Telegr & Teleph Corp <Ntt> | 構造変化検出方法および通信網異常状態検出方法、並びに、その装置およびプログラム |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
EP3939613A1 (en) * | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
SI2838918T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul |
SG10201705787VA (en) | 2012-09-27 | 2017-08-30 | Merus Nv | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
JP7230819B2 (ja) * | 2017-10-06 | 2023-03-01 | 小野薬品工業株式会社 | 二重特異性抗体 |
-
2020
- 2020-07-29 CA CA3149309A patent/CA3149309A1/en active Pending
- 2020-07-29 MX MX2022000971A patent/MX2022000971A/es unknown
- 2020-07-29 AU AU2020322765A patent/AU2020322765A1/en not_active Abandoned
- 2020-07-29 JP JP2020570992A patent/JP6856183B1/ja active Active
- 2020-07-29 BR BR112022001473A patent/BR112022001473A2/pt unknown
- 2020-07-29 US US17/630,426 patent/US20220281977A1/en active Pending
- 2020-07-29 WO PCT/JP2020/028972 patent/WO2021020416A1/ja active Application Filing
- 2020-07-29 EP EP20846826.4A patent/EP4008348A4/en active Pending
- 2020-07-29 CN CN202080054077.0A patent/CN114174343A/zh active Pending
- 2020-07-29 KR KR1020227003026A patent/KR20220039720A/ko unknown
- 2020-07-29 TW TW109125604A patent/TW202118790A/zh unknown
-
2021
- 2021-02-19 JP JP2021025286A patent/JP2021075580A/ja active Pending
-
2022
- 2022-01-23 IL IL290050A patent/IL290050A/en unknown
- 2022-01-26 ZA ZA2022/01247A patent/ZA202201247B/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110280878A1 (en) * | 2003-01-23 | 2011-11-17 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
US20120003210A1 (en) * | 2003-11-12 | 2012-01-05 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
KR101027427B1 (ko) * | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
EP2147594B1 (en) * | 2008-06-27 | 2013-11-13 | Merus B.V. | Antibody producing non-human mammals |
US20190211100A1 (en) * | 2015-07-10 | 2019-07-11 | Merus N.V. | Human CD3 Binding Antibody |
US20180186875A1 (en) * | 2015-09-25 | 2018-07-05 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
US20180355061A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that Specifically Bind PD-1 and Methods of Use |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "Effect of Individual Fc Methionine Oxidation on FcRn Binding: Met252 Oxidation Impairs FcRn Binding More Profoundly than Met428 Oxidation - ScienceDirect", 3 January 2016 (2016-01-03), pages 1 - 4, XP093055241, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/abs/pii/S0022354915301969?via=ihub> [retrieved on 20230618] * |
KEVIN O. SAUNDERS ET AL: "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1296, XP055654839, DOI: 10.3389/fimmu.2019.01296 * |
PALUCH CHRISTOPHER ET AL: "Immune Checkpoints as Therapeutic Targets in Autoimmunity", FRONTIERS IN IMMUNOLOGY, vol. 9, 8 October 2018 (2018-10-08), pages 1 - 11, XP093055022, DOI: 10.3389/fimmu.2018.02306 * |
SIMON KRAH ET AL: "Engineering IgG-Like Bispecific Antibodies-An Overview", ANTIBODIES, vol. 7, no. 3, 1 August 2018 (2018-08-01), CH, pages 28, XP055602846, ISSN: 2073-4468, DOI: 10.3390/antib7030028 * |
TO R ET AL: "Isolation of Monomeric Human VHS by a Phage Selection", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 280, no. 50, 16 December 2005 (2005-12-16), pages 41395 - 41403, XP009100333, ISSN: 0021-9258, DOI: 10.1074/JBC.M509900200 * |
Also Published As
Publication number | Publication date |
---|---|
JP2021075580A (ja) | 2021-05-20 |
EP4008348A1 (en) | 2022-06-08 |
AU2020322765A1 (en) | 2022-02-24 |
ZA202201247B (en) | 2023-08-30 |
IL290050A (en) | 2022-03-01 |
JPWO2021020416A1 (ja) | 2021-09-13 |
MX2022000971A (es) | 2022-02-14 |
CA3149309A1 (en) | 2021-02-04 |
JP6856183B1 (ja) | 2021-04-07 |
TW202118790A (zh) | 2021-05-16 |
CN114174343A (zh) | 2022-03-11 |
WO2021020416A1 (ja) | 2021-02-04 |
BR112022001473A2 (pt) | 2022-03-22 |
US20220281977A1 (en) | 2022-09-08 |
KR20220039720A (ko) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3903817A4 (en) | NEW ANTI-CCR8 ANTIBODY | |
EP3941944A4 (en) | B-SPECIFIC CLAUDIN-6 ANTIBODIES | |
EP4008730A4 (en) | BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES | |
EP3986936A4 (en) | ANTI-TIGIT ANTIBODIES | |
EP3763743A4 (en) | BISPECIFIC ANTIBODY | |
EP3885367A4 (en) | ANTI-HER2/PD1 BISPECIFIC ANTIBODY | |
EP3784699A4 (en) | OPTIMIZED ANTI-TL1A ANTIBODIES | |
EP3746120A4 (en) | ANTI-PD-1 ANTIBODY | |
EP3866851A4 (en) | BISPECIFIC ANTIBODIES TARGETING EXOSOMES | |
EP3752536A4 (en) | ANTI-HER2 ANTIBODIES | |
EP3626745A4 (en) | RECOMBINANT BISPECIFIC ANTIBODY | |
EP4144370A4 (en) | BISPECIFIC ANTIBODY | |
EP3831851A4 (en) | ANTI-BTLA ANTIBODIES | |
EP3693013A4 (en) | BISPECIFIC ANTIBODY | |
AU2019361253A1 (en) | Anti-synuclein antibodies | |
EP3733713A4 (en) | BISPECIFIC ANTIBODIES AND ITS APPLICATIONS | |
EP3768724A4 (en) | NOVEL ANTI-PD-1 ANTIBODIES | |
EP3852779A4 (en) | ANTI-KLRG1 ANTIBODIES | |
IL286757A (en) | Antibodies in specific | |
EP3995582A4 (en) | ANTI-EPHA4 ANTIBODIES | |
EP3986462A4 (en) | ANTI-TIM-3 ANTIBODIES | |
EP3998286A4 (en) | QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES | |
IL286918A (en) | Bispecific antibody | |
EP4081546A4 (en) | NEW ANTI-FGFR2B ANTIBODIES | |
EP4034568A4 (en) | NOVEL ANTI-PD-L1 ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/13 20060101ALI20230626BHEP Ipc: C07K 16/46 20060101ALI20230626BHEP Ipc: C07K 16/28 20060101ALI20230626BHEP Ipc: C07K 16/18 20060101ALI20230626BHEP Ipc: A61P 37/06 20060101ALI20230626BHEP Ipc: A61K 39/395 20060101AFI20230626BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231013 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/13 20060101ALI20231009BHEP Ipc: C07K 16/46 20060101ALI20231009BHEP Ipc: C07K 16/28 20060101ALI20231009BHEP Ipc: C07K 16/18 20060101ALI20231009BHEP Ipc: A61P 37/06 20060101ALI20231009BHEP Ipc: A61K 39/395 20060101AFI20231009BHEP |